Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain. - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

February 9, 2006

Last Updated Date

March 21, 2008

Start Date ^†

March 2006

Current Primary Outcome Measures ^†

To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6.

Original Primary Outcome Measures ^†

Same as current

Change History

Complete list of historical versions of study NCT00290901 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

To compare the effects of treatment with celecoxib 200 mg BID and tramadol hydrochloride 50 mg QID on improvement in functionality and quality of life in subjects with chronic low back pain.

Original Secondary Outcome Measures ^†

Same as current

Descriptive Information

Brief Title ^†

Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.

Official Title ^†

A Six Week Double-Blind, Randomized, Multicenter Comparison Study of the Analgesic Effectiveness of Celecoxib 200 mg BID Compared to Tramadol Hydrochloride 50 mg QID in Subjects With Chronic Low Back Pain

Brief Summary

This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.

Detailed Description

Study Phase

Phase IV

Study Type ^†

Interventional

Study Design ^†

Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study

Condition ^†

Back Pain

Intervention ^†

Drug: Tramadol Hydrochloride 50mg
Drug: Celebrex 200mg

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Completed

Enrollment ^†

754

Completion Date

Primary Completion Date

December 2006 (final data collection date for primary outcome measure)

Eligibility Criteria ^†

Inclusion Criteria:

The subject presents with duration of chronic low back pain of > 3 months requiring regular use of analgesics (> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used.

Exclusion Criteria:

The subject has chronic low back pain, which is neurologic in etiology (i.e., radiculopathy, neuropathy, myelopathy)

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Yes

Contacts ^††

Location Countries ^†

United States, Puerto Rico

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00290901

Responsible Party

Secondary IDs ^††

Study Sponsor ^†

Pfizer

Collaborators ^††

Investigators ^†

Study Director:

Pfizer CT.gov Call Center

Pfizer

Information Provided By

Pfizer

Verification Date

March 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.